Acute myeloid leukemia with myelodysplasia-related changes

American Journal of Clinical Pathology

Volumn 144, Issue 1, 2015, Pages 29-43

  Vardiman, James ^a   Reichard, Kaaren ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Acute leukemia; AML, NPM1; Myelodysplasia

Indexed keywords

PROTEIN P53;

5Q- SYNDROME; ACUTE MYELOBLASTIC LEUKEMIA; APLASTIC ANEMIA; BONE MARROW DEPRESSION; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 5; CHROMOSOME ABERRATION; CONFERENCE PAPER; DYSPLASIA; FANCONI ANEMIA; GENE FREQUENCY; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; KARYOTYPE; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; NEAR TETRAPLOIDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TETRAPLOIDY; FEMALE; GENETICS; MALE; PATHOLOGY;

FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES;

EID: 84939451519     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP58RSMFRHLHHH     Document Type: Conference Paper

References (54)

1. Bennett JM,Catovsky D,Daniel MT,et al Proposals for the classification of the myelodysplastic syndromes Br J Haematol. 1982; 51: 189-199.
2. Brunning RD, Matutes E, Harris NL, et al. Acute myeloid leukemia with multilineage dysplasia. In: Jaffe E, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 3rd ed. Lyon, France: IARC; 2001:88-89.
3. Arber DA, Stein AS, Carter NH, et al. Prognostic impact of acute myeloid leukemia class ification: importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol. 2003;119:672-680.
4. Wakui M, Kuriyama K, Miyazaki Y, et al. Di agnosis of acute myeloid leukemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol. Int J Hematol. 2008;87:144-151.
5. Yanada M, Suzuki M, Kawashima K, et al . Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience. Eur J Haematol. 2005;74:418-423.
6. Miyazaki Y, Kuriyama K, Miyawaki S, et al. Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study. Br J Haematol. 2003;120:56-62.
7. Weinberg OK, Seetharam M, Ren L, et al . Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009;113:1906-1908.
8. Rozman M, Navarro JT, Ar enillas L, et al. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediaterisk cytogenetics and wild-type NPM1. Ann Hematol. 2014;93:1695-1703.
9. Haferlach T, Schoch C, Loffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induc tion therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol. 2003;21:256-265.
10. Wandt H, Schakel U, Kroschinsky F, et al. MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. Blood. 2008;111:1855-1861.
11. Miesner M, Haferlach C, Bacher U, et al . Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not ot herwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC). Blood. 2010;116:2742-2751.
12. Arber DA Brunning RD, Orazi A, et al. Acute myeloid leukaemia with myelodysplasia-related changes. In: Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008:124-126.
13. Falini B, Macijewski K, Weiss T, et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood. 2010;115:3776-3786.
14. Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood. 2011;117:1109-1120.
15. Malcovati L, Pap aemmanuil E, Ambaglio I, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014;124:1513-1521.
16. Fernandez-Mercado M, Burns A, Pellagatti A, et al. Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes. Haematologica. 2013;98:1856-1864.
17. Patnaik MM, Lasho TL, Finke CM, et al. Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients. Am J Hematol. 2011;86:393-398.
18. Qian Z, Joslin JM, Tennant TR, et al. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem Biol Interact. 2010;184:50-57.
19. Hasserjian RP LeBeau MM, List AF, et al. Myelodysplastic syndrome with isolated del(5q). In: Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008:102.
20. Geyer JT, Verma S, Mathew S, et al. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q). Hum Pathol. 2013;44:346-356.
21. Mallo M, Cervera J, Schanz J, et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia. 2011;25:110-120.
22. Ingram W, Lea NC, Cervera J, et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia. 2006;20:1319-1321.
23. Volkert S, Kohlmann A, Schnittger S, et al. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome. Genes Chrom Cancer. 2014;53:402-410.
24. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a disti nct HOX gene expression pattern. Blood. 2011;118:3645-3656.
25. Akiki S, Dyer SA, Grimwade D, et al. NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant s ubgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR. Genes Chrom Cancer. 2013;52:1053-1064.
26. Haferlach C, Dicker F, Herholz H, et al. Mut ations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia. 2008;22:1539-1541.
27. Bally C, Ades L, Renneville A, et al. Prognostic valu e of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leuk Res. 2014;38:751-755.
28. Kulasekararaj AG, Smith AE, Mian SA, et al. TP53 mutation s in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol. 2013;160:660-672.
29. Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119:2114-2121.
30. Seifert H, Mohr B, Thiede C, et al. The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia. 2009;23:656-663.
31. Lazarus HM, Litzow MR. AML cytogenetics: the complex just got simpler. Blood. 2012;120:2357-2358.
32. Zhang JH, Zheng YC, Wang YX, et al. Enlarged and prominent nucleus may be indicative of tetraploidy: a laboratory study of a rare near-tet raploidy in a child patient with acute myelogenous leukemia AML-M4. J Pediatr Hematol Oncol. 2010;32:19-21.
33. Clarke MR, Lynch EF, Contis LC, et al. Near-tetraploidy in adult acute myelogenous leukemia. Cancer Genet Cytogenet. 1996;86:107-115.
34. Xue Y, Pan Y, Liu Z, et al. Tetraploid or near-tetraploid clones characterized by two 8;21 translocations and other chromosomal abnormalitie s in two patients with acute myeloblastic leukemia. Cancer Genet Cytogenet. 1996;92:18-23.
35. Davoli T, Denchi EL, de Lange T. Persistent telomere damage induces bypass of mitosis and tetraploidy. Cell. 2010;141:81-93.
36. Senovilla L, Vitale I, Martins I, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science. 2012;337:1678-1684.
37. Senovilla L, Galluzzi L, Castedo M, et al. Immunological control of cell cycle aberrations fo r the avoidance of oncogenesis: the case of tetraploidy. Ann NY Acad Sci. 2013;1284:57-61.
38. Xiao Z, Liu S, Liu X, Yu M, et al. Tetraploidy or neartetraploidy clones with double 8;21 translocati on: a non-random additional anomaly of acute myeloid leukemia with t(8;21)(q22;q22). Haematologica. 2005;90:413-414.
39. Liew E, Owen C. Familial myelodysplastic syndromes: a review of the literature. Haematologica. 2011;96:1536-1542.
40. Parikh S, Bessler M. Recent insights into inherited bone marrow failure syndromes. Curr Opin Pediatr. 2012;24:23-32.
41. Wilson DB, Link DC, Mason PJ, et al. Inherited bone marrow failure syndromes in adolescents and young adults. Ann Med. 2014;46:353-363.
42. Mehta PA, Harris RE, Davies SM, et al. Numerical chromosomal changes and risk of development of myelodysplastic syndrome-Acute myeloid leukemia in patients with Fanconi anemia. Cancer Genet Cytogenet. 2010;203:180-186.
43. Alter BP, Carus o JP, Drachtman RA, et al. Fanconi anemia: myelodysplasia as a predictor of outcome. Cancer Genet Cytogenet. 2000;117:125-131.
44. Berger R,Le Coniat M,Schaison G Chromosome abnormalities in bone marrow of Fanconi anemia patients Cancer Genet Cytogenet. 1993; 65: 47-50.
45. Hahn CN, Chong CE, Carmichael CL, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 2011;43:1012-1017.
46. Holme H, Hossain U, Kirwan M, et al. Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia. Br J Haematol. 2012;158:242-248.
47. West AH, Godley LA, Churpek JE. Familial myelodysplastic syndrome/acute leukemia syndromes: a rev iew and utility for translational investigations. Ann NY Acad Sci. 2014;1310:111-118.
48. Pippucci T, Savoia A, Perrotta S, et al. Mutations in the 5? UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet. 2011;88:115-120.
49. Noris P, Favier R, Alessi MC, et al. ANKRD26-related thrombocytopenia and myeloid malignancies. Blood. 2013;122:1987-1989.
50. Gaitonde S, Boumendjel R, Angeles R, et al. Familial childhood monosomy 7 and associated myelodysplasia. J Pediatric Hematol Oncol. 2010;32:e236-e237.
51. Maciejewski JP, Risitano A, Sloand EM, et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002;99:3129-3135.
52. Bagby GC, Meyers G. Bone marrow failure as a risk factor for clonal evolution: prospects for leukemia prevention. Hematology Am Soc Hematol Educ Program. 2007:40-46.
53. Young NS. Current concepts in the pathophysiology and treatment of aplastic anemia. Hematology Am Soc Hematol Educ Program. 2013:76-81
54. Dolberg OJ, Levy Y. Idiopathic aplastic anemia: diagnosis and classification. Autoimmun Rev. 2014;13:569-573.